2019 has been a rough year for Verastem Oncology (VSTM) and its shareholders. Despite some positive developments and changes in the C-Suite, the company's flagship product, COPIKTRA, has struggled to impress the Street during its first year on the market. As a result, the VSTM share price and investor sentiment continue to disintegrate as we approach 2020. However, I have found some bullish signals that have provided me enough evidence to add to my speculative position.
I intend to review some of the recent updates and point out some bullish signals among the